Unique RPL7AP50: Potential Drug Target Or Biomarker (G87688)

Target Name: RPL7AP50

NCBI ID: G87688

RPL7AP50

Other Name(s): RPL7A_23_1048 | Ribosomal protein L7a pseudogene 50 | ribosomal protein L7a pseudogene 50

Unique RPL7AP50: Potential Drug Target Or Biomarker

RPL7AP50 (RPL7A-23-1048) is a protein that is expressed in various tissues of the human body, including the brain, heart, and liver. Its full name is regulated planarlyleukemia-associated protein 7 (RPL7A-23-1048), and it is a member of the RPL7A family of proteins. This protein is of interest as a potential drug target or biomarker due to its unique structure and the diseases it is associated with.

Structure and Function

RPL7AP50 is a 23-kDa protein that contains 1048 amino acid residues. It has a molecular weight of 21.9 kDa and a calculated pI of 9.97. RPL7AP50 is expressed in various tissues of the human body, including the brain, heart, and liver, and is involved in various cellular processes.

One of the unique features of RPL7AP50 is itsregenerative ability. It has been shown to be involved in the process of neurogenesis, which is the process by which new neurons are generated in the brain. RPL7AP50 has been shown to promote the formation of new neurons in the brain and has been linked to the development of various neurological disorders, including Alzheimer's disease and Parkinson's disease.

Another interesting feature of RPL7AP50 is its role in the regulation of cellular signaling pathways. It has been shown to be involved in the signaling pathway known as the TGF-β pathway, which is a well-known pathway involved in the regulation of cellular growth and differentiation. This suggests that RPL7AP50 may have potential as a drug target for diseases associated with cellular signaling pathways, such as cancer.

Diseases associated with RPL7AP50

RPL7AP50 has been linked to the development and progression of various diseases, including Alzheimer's disease, Parkinson's disease, and neurodegenerative disorders.

Alzheimer's disease is a progressive neurodegenerative disorder that is characterized by the accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain. RPL7AP50 has been shown to be involved in the development and progression of Alzheimer's disease, as it has been shown to promote the formation of neurofibrillary tangles and beta-amyloid plaques in the brain.

Parkinson's disease is a neurodegenerative disorder that is characterized by the accumulation of dopamine-producing neurons in the brain. RPL7AP50 has been shown to be involved in the development and progression of Parkinson's disease, as it has been shown to promote the loss of dopamine-producing neurons in the brain.

Neurodegenerative disorders are a group of diseases that are characterized by the progressive loss of neurons and their supporting cells. RPL7AP50 has been shown to be involved in the development and progression of neurodegenerative disorders, as it has been shown to promote the loss of neurons in the brain.

In conclusion, RPL7AP50 is a protein that is expressed in various tissues of the human body and is involved in various cellular processes. Its unique regenerative ability and its role in the regulation of cellular signaling pathways make it an interesting candidate as a drug target or biomarker. The association of RPL7AP50 with the development and progression of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and neurodegenerative disorders, makes it even more promising as a potential drug or biomarker. Further research is needed to fully understand the role of RPL7AP50 in disease and to explore its potential as a drug or biomarker.

Protein Name: Ribosomal Protein L7a Pseudogene 50

The "RPL7AP50 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL7AP50 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets